Chioggia

Researchers are evaluating the best way to give intravenous loop diuretics, specifically furosemide, to patients admitted with acute decompensated heart failure (ADHF). This observational study compares continuous infusion with intermittent bolus infusion of furosemide. The goal is to better understand which method improves kidney function, reduces fluid congestion, and affects heart-related outcomes. Previous smaller studies helped design this larger trial to clarify optimal dosing and administration. Participants receive one of two treatments: continuous intravenous infusion of furosemide or intermittent intravenous bolus infusions. Both methods aim to reduce fluid buildup and ease heart failure symptoms. Continuous infusion could provide steadier drug delivery, potentially protecting kidney function better than intermittent doses. The study carefully monitors signs of fluid congestion and measures blood levels of B-type Natriuretic Peptide (BNP), a marker related to heart stress. During the study, patients are assessed for kidney function, congestion signs, and heart failure outcomes, including cardiac death and rehospitalization over 180 days. Researchers collect data on how the different infusion strategies impact these measures. The study involves clinical evaluations, laboratory tests including BNP levels, and follow-up visits to monitor participants' health over the study period.